KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Shares Outstanding (Diluted Average) for 13 consecutive years, with $89.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 13.09% year-over-year to $89.2 million, compared with a TTM value of $89.2 million through Dec 2025, up 13.09%, and an annual FY2025 reading of $89.2 million, up 13.09% over the prior year.
  • Shares Outstanding (Diluted Average) was $89.2 million for Q4 2025 at Travere Therapeutics, roughly flat from $88.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $89.2 million in Q4 2025 and bottomed at $56.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $72.3 million, with a median of $73.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) soared 30.53% in 2021, then increased 1.53% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $59.8 million in 2021, then grew by 6.56% to $63.8 million in 2022, then rose by 16.48% to $74.3 million in 2023, then rose by 6.22% to $78.9 million in 2024, then grew by 13.09% to $89.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TVTX at $89.2 million in Q4 2025, $88.8 million in Q3 2025, and $88.7 million in Q2 2025.